Recent Updates
Recently added Catalysts
NEUP Neutral Sentiment Score: 60/100

Scheme Implementation Agreement - Amending Agreement Date : 24 October 2024 Parties Bionomics Name Bionomics Limited (a company incorporated in South Australia) ACN 075 582 740 Address 200 Greenhill Road, Eastwood SA 506

Key Takeaway: Bionomics Limited and Neuphoria Therapeutics Inc. have amended their Scheme Implementation Agreement dated October 1, 2024. The amendments detailed in the document take effect immediately and clarify various aspects including the roles of ADS and shareholders. This agreement aims to facilitate the transfer of Bionomics shares to Neuphoria under the specified arrangement conditions. Key provisions emphasize the operational and legal framework for this corporate action.

Market Sentiment Analysis

Full Press Release Details

Scheme Implementation Agreement - Amending Agreement
Date: 24 October 2024
Bionomics Name Bionomics Limited (a company incorporated in South Australia)
ACN 075 582 740
Address 200 Greenhill Road, Eastwood SA 5063
Email [redacted]
Attention Spyridon "Spyros" Papapetropoulos, M.D.
Neuphoria Name Neuphoria Therapeutics Inc. (a company incorporated in Delaware)
Address 100 Summit Dr, Burlington, MA 01803 USA
Email [redacted]
Attention Spyridon "Spyros" Papapetropoulos, M.D.
Operative provisions
Capitalised terms in this document
have the same meanings as in the Agreement unless the context requires otherwise.
The Agreement is amended as follows.
"4.2 Scheme Consideration
The amendments to the Agreement which
are set out in this document take effect on and from the date of this document as specified above.
Other than as varied by this document,
the terms and conditions of the Agreement remain in full force and effect.
This document may be signed in counterparts and all counterparts
taken together constitute one document.
Executed as an agreement
Executed by )
Bionomics Limited )
in accordance with section 127 of the Corporations Act 2001 (Cth): )
/Spyridon Papapetropoulos/ _________ /Alan Fisher/ _________
Signature of Director Signature of Director/Secretary
Spyridon Papapetropoulos _________ Alan Fisher _________
Name of Director/Secretary (print) Name of Director/Secretary (print)
Executed by )
Neuphoria Therapeutics Inc. )
In accordance with its constituent documents and laws of its place of incorporation: )
/Spyridon Papapetropoulos/_________
Spyridon Papapetropoulos, M.D. Chief Executive Officer
Annexure A - Scheme of Arrangement
Scheme of Arrangement
SCHEME OF ARRANGEMENT
Under section 411 of the Corporations Act
THE PARTIES AGREE AS FOLLOWS:
Unless the contrary intention appears,
these meanings apply:
ADS means an American Depositary
ADS Depositary means Citibank,
ADS Holder means a holder of
ASIC means the Australian Securities
& Investments Commission.
Bionomics ADS means each American
Depositary Share, representing 180 Bionomics Shares and which trade on Nasdaq under the ticker code "BNOX".
Bionomics Share means each fully
paid ordinary share in Bionomics.
Bionomics Shareholder means
each person entered in the Register as a holder of Bionomics Shares.
Business Day means a day (other
than a Saturday, Sunday or public holiday) on which banks are open for general banking business in Adelaide, South Australia or Delaware,
Completion means completion
of the implementation of the Scheme on the Implementation Date.
Corporations Act means the Corporations
Court means Supreme Court of
New South Wales or such other court of competent jurisdiction as the parties may agree in writing.
Deed Poll means the deed poll
dated 23 October 2024 executed by Neuphoria substantially in the form of Annexure D of the Scheme Booklet or as otherwise agreed by Neuphoria
and Bionomics under which Neuphoria covenants in favour of each Scheme Participant to perform its obligations under this Scheme.
Effective means the coming into
effect, under section 411(10) of the Corporations Act, of the order of the Court made under section 411(4)(b) of the Corporations Act
in relation to the Scheme, but in any event at no time before an office copy of the order of the Court is lodged with ASIC.
Effective Date means the date
on which the Scheme becomes Effective.
Encumbrance means any security
for the payment of money or performance of obligations, including a mortgage, charge, lien, pledge, trust, power or title retention or
flawed deposit arrangement and any "security interest" as defined in sections 12(1) or 12(2) of the PPSA or any agreement
to create any of them or allow them to exist.
End Date means the Sunset Date,
including any extension to that date, as defined in the Scheme Implementation Agreement.
Excluded Shareholder means Neuphoria
and any of its subsidiaries.
Implementation Date means the
fifth Business Day following the Record Date or such other date as the parties agree in writing.
Ineligible Overseas Shareholder
means a Bionomics Shareholder:
and Bionomics jointly determine that it is lawful and not unduly onerous and not unduly impracticable to issue that Bionomics Shareholder
with Neuphoria Shares when the Scheme becomes Effective and it is lawful for that Bionomics Shareholder to participate in the Scheme by
the law of such other place as a Bionomics Shareholder may be resident or located.
Nasdaq means the Nasdaq Global
Neuphoria means Neuphoria Therapeutics Inc., a Delaware
Neuphoria Share means a share
of common stock in Neuphoria.
New Neuphoria Shares means Neuphoria
Shares to be issued under the Scheme as Scheme Consideration.
Non-Electing Small Parcel Holder
means a Small Parcel Holder who has not made a valid election to not participate in the Sale Facility, or having made such an election
has validly withdrawn their election.
Permitted Jurisdiction means
Australia, Canada, European Union (excluding Austria), Hong Kong, Jersey, Kazakhstan, Mexico, New Zealand, Norway, Singapore, South Africa,
Switzerland, South Korea, the United Kingdom, the United States and any other jurisdictions mutually agreed by Bionomics and Neuphoria.
PPSA means the Personal Property
Securities Act 2009 (Cth).
Record Date means 7.00 pm on
the second Business Day following the Effective Date, or any other date (after the Effective Date) agreed by the parties to be the record
date to determine entitlements to receive Scheme Consideration under the Scheme.
Register means the register
of members of Bionomics.
Registered Address means, in
relation to a Bionomics Shareholder, the address shown in the Register.
Sale Facility means the facility
to be conducted in accordance with clause 6.4.
Scheme means this scheme of
arrangement between Bionomics and Scheme Participants under which all of the Scheme Shares will be transferred to Neuphoria under Part
5.1 of the Corporations Act as described in clause 6 of this Scheme, in consideration for the Scheme Consideration, subject to any amendments
or conditions made or required by the Court pursuant to section 411(6) of the Corporations Act to the extent they are approved in writing
by Bionomics and Neuphoria in accordance with clause 10 of this Scheme.
Scheme Booklet means the information
prepared in accordance with the Scheme Implementation Agreement and agreed by the parties (acting reasonably) to be approved by the Court
and despatched to Scheme Participants in relation to the Scheme.
Scheme Consideration in relation
to a Scheme Participant means the number of New Neuphoria Shares to be issued to the Scheme Participant as described in clause 6.2.
Scheme Implementation Agreement
means the scheme implementation agreement dated 1 October 2024 between Bionomics and Neuphoria under which, amongst other things, Bionomics

Frequently Asked Questions

What is the date of the Scheme Implementation Agreement?

The Scheme Implementation Agreement is dated 24 October 2024.

What does the Scheme Consideration refer to?

Scheme Consideration refers to the number of New Neuphoria Shares issued to each Scheme Participant.

Where is Bionomics Limited incorporated?

Bionomics Limited is incorporated in South Australia.

What is the Effective Date of the Scheme?

The Effective Date is the date when the Scheme becomes Effective as per the Corporations Act.

Who executes the Agreement on behalf of Neuphoria?

Spyridon Papapetropoulos, M.D., the CEO, executes the Agreement for Neuphoria.

Last updated: Nov 8, 2024